Therapeutic Plasma Exchange (TPE): Cost, Benefits, Risks and Evidence

Therapeutic plasma exchange (TPE) is not a detox hack or a guaranteed rejuvenation treatment. If you are searching for therapeutic plasma exchange cost, start with the clinical caveat: pricing should not be judged as a standalone session fee because labs, replacement fluid, physician supervision and follow-up change the real budget. It is a supervised medical procedure that removes part of a person's plasma and replaces it with albumin or compatible donor plasma while returning the blood cells. It has decades of use in hospitals for immune, neurological and hematological conditions. In longevity medicine, the narrower question is whether reducing inflammatory plasma factors and senescence signals can improve measurable biology in carefully selected people.

Quick answer: TPE cost, evidence and safety

• Definition: therapeutic plasma exchange removes plasma and replaces it with albumin or compatible donor plasma while returning red cells, white cells and platelets.
• Cost: public private-market references often sit around 1,500-4,500 EUR in parts of Europe and $5,000-$10,000+ in U.S. wellness settings, but quotes are not comparable unless they include labs, replacement fluid, venous access, medical supervision and follow-up.
• Evidence: TPE is established for specific ASFA-guided diseases; longevity use remains investigational and should be tied to biomarkers, consent and stopping rules.
• Session time: hospital apheresis units commonly describe sessions around 2-3 hours, depending on body weight, plasma volume, access and replacement strategy.
• Before booking: ask which technique is used, how much plasma is exchanged, which labs are checked, who signs the indication and what data decides whether to repeat or stop.

Established indications vs investigational uses

Use	Evidence status	Practical reading
Hospital indications	ASFA 2023 categorizes 166 therapeutic apheresis indications from category I to IV. TPE may be first-line, supportive or case-by-case depending on the disease.	TTP, Guillain-Barré syndrome, myasthenia gravis, hyperviscosity or antibody-mediated rejection require specialist assessment and clinical guidelines.
Longevity	Investigational/off-label use to study inflammation, proteomics, immunity and biological clocks.	It is not an ASFA anti-aging indication. It requires consent, biomarkers, stopping rules and review of less invasive alternatives.
Microplastics	Early 2025-2026 data suggest removal or reduction of circulating particles in some protocols and profiles.	It does not prove lower tissue burden, fewer diseases or longer healthspan. It should not be sold as guaranteed removal.

In 2025, a small exploratory clinical trial from the Buck Institute for Research on Aging reported that therapeutic plasma exchange combined with immunoglobulin reduced average biological age by 2.61 years in adults over 50 (Fuentealba et al., Aging Cell 2025). Biweekly TPE without IVIG showed a smaller average reduction of 1.32 years. That is promising, but it is not a clinical guarantee: the trial was small, single-blind, short-term and needs independent replication. TPE should be considered only after blood tests, medical review and a clear risk-benefit discussion.

There is also contrary evidence. A 2025 Scientific Reports trial in healthy donors (Borsky et al., PMID: 40592961) tested 4 or 8 plasmapheresis sessions over 18 weeks without young plasma or albumin replacement. Lipids, proteins and minerals changed, but no significant epigenetic rejuvenation was observed; DNAmGrimAge, the Hannum clock and Dunedin Pace of Aging increased. The practical takeaway is simple: not every plasmapheresis protocol rejuvenates. Protocol, replacement fluid, baseline health and clinical goal matter.

TL;DR: benefits, risks and cost

• What it does: filters plasma to reduce circulating inflammatory proteins, autoantibodies and some protein-bound plasma components.
• What the evidence suggests: small human studies show improved inflammatory and proteomic markers; one 2025 controlled trial reported biological-age improvements, while another healthy-donor trial did not show epigenetic rejuvenation.
• Who may benefit: people with elevated inflammation, immune dysregulation, autoantibodies or relevant environmental exposure — only after medical screening.
• Main risks: bruising, dizziness, fatigue, electrolyte shifts, allergic reactions and infection risk if not performed under strict clinical protocols.
• Typical cost: usually a high-supervision, four-figure medical budget rather than a simple wellness add-on; protocol, replacement fluid, labs and physician oversight matter more than the headline price.

How to separate evidence from marketing in TPE

Current search results mix medical definitions, regenerative-medicine clinic pages and international longevity articles. Some are helpful; others blur very different procedures. The safe way to read them is to ask what is measured and what remains a hypothesis.

A serious TPE page should distinguish albumin-based TPE, double filtration, donor plasma, IVIG and plasma donation. They do not have the same cost, purpose or evidence level. It should also state that ASFA guidelines support specific medical indications, not a general “anti-aging” indication for healthy adults.

Clinical sources use much more precise language: Cleveland Clinic describes plasma exchange as removing plasma, replacing it with fluid and returning the blood cells; the American College of Rheumatology frames it as a way to remove harmful antibodies or proteins in selected diseases; UT Southwestern notes that one procedure typically removes about 65-70% of disease-causing plasma proteins, usually as part of a series; and Johns Hopkins presents it as an apheresis intervention that requires indication, clinical preparation and follow-up. That is the difference between medicine and “blood washing” marketing.

The red flag is not advanced technology itself. The red flag is a promise of total detox, guaranteed microplastic removal or years of rejuvenation without baseline labs, physician supervision, risk review, replacement-fluid details and a stop rule. In longevity medicine, plasma exchange is only defensible when it answers a measurable clinical question.

In this guide, we explain what therapeutic plasma exchange is, how it works step by step, what it can remove from plasma, what the latest science says, what it is used for in conventional medicine, what recovery usually looks like and what limits remain when it is considered for longevity.

Before considering a session, place it inside a plan: compare the Optimization Program, review medical treatments and diagnostics, understand what a longevity clinic should measure, read the practical guide to plasmapheresis step by step, review the cost of a longevity program and, when appropriate, request an initial assessment.

Question	Short answer	Clinical note
TPE vs plasmapheresis	Often used interchangeably in therapeutic contexts.	Technically, plasma exchange includes replacement fluid; it is different from plasma donation or diagnostic sampling.
Longevity benefit	May reduce inflammatory and age-related plasma factors.	Evidence is promising but still developing.
Microplastics	Early 2025-2026 studies suggest removal or reduction of circulating particles in some protocols.	No proven clinical outcome, tissue-burden or longevity benefit yet.
Safety	Generally well tolerated with trained teams and screening.	Not appropriate for everyone; labs and medical history matter.

What Is Therapeutic Plasma Exchange (TPE)?

Therapeutic plasma exchange (TPE) is a medical procedure in which blood is removed from the patient, plasma is separated from the cellular components, part of that plasma is removed and replaced with albumin or compatible donor plasma. Red blood cells, white blood cells and platelets are returned to the body.

Terminology: TPE, plasmapheresis and plasma exchange

In everyday clinical language these terms are often used interchangeably, but the distinction matters. Plasmapheresis describes separating or removing plasma; therapeutic plasma exchange (TPE) or plasma exchange means removing a clinically relevant plasma volume and replacing it with albumin, compatible donor plasma or another indicated fluid. It should not be confused with diagnostic plasma collection, small-volume plasma sampling or plasma donation.

How It Works: Step by Step

1. Blood extraction: Two intravenous lines are placed (typically one in each arm). One line extracts blood; the other returns it, allowing continuous flow.
2. Centrifugation: Blood passes through a machine that centrifuges it, separating it into three components: plasma (the liquid, yellowish part containing proteins, antibodies and soluble mediators), red blood cells (carry oxygen), and platelets and white blood cells (clotting and immunity).
3. Plasma removal: Plasma is discarded or filtered depending on the protocol. This compartment contains autoantibodies, fibrinogen, immune complexes, inflammatory proteins and some particles or compounds bound to plasma proteins.
4. Replacement with albumin: The removed plasma is replaced with a solution of human albumin (a purified, safe, and well-tolerated protein) or donor plasma. Albumin maintains the body's fluid and protein balance.
5. Return of blood components: Red blood cells, platelets and white blood cells are returned to the patient with plasma volume restored.

Typical duration: hospital apheresis units often describe sessions of about 2-3 hours; the real time depends on body weight, hematocrit, venous access, exchanged plasma volume and replacement strategy.

What Does Therapeutic Plasma Exchange Remove?

TPE does not “detox everything” and it does not replace the liver or kidneys. Its advantage is narrower: it acts on the plasma compartment, where autoantibodies, immune complexes, fibrinogen, inflammatory mediators and some protein-bound compounds circulate.

Microplastics and Nanoplastics: early signal, not a clinical promise

A study published in Environment International (2022) detected microplastics in the blood of 77% of people analyzed. These particles come from food packaging, synthetic clothing, tires, cosmetics, and the degradation of plastics in the environment.

A 2025 study in Brain Medicine (PMC12162106) provided an early signal that double-filtration therapeutic apheresis may remove microplastic-like particles from extracted material. In 21 patients with post-infectious chronic fatigue syndrome, 14 polymer-like signals were detected in the eluate, including polyamide 6 (nylon 6) and polyurethane. The caveat matters: the authors did not quantify total blood microplastic reduction or prove direct clinical benefit.

In 2026, Weinstein et al. published a Journal of Clinical Apheresis study of 114 people and 174 plasma exchange procedures. In participants with moderate-to-high starting levels, TPE was associated with lower circulating microplastic counts; in people with very low starting levels, contamination from plastic tubing or circuit materials can complicate interpretation. The responsible interpretation is narrow: lower measured particles in blood does not yet prove lower total body burden, lower disease risk or longer healthspan.

Inflammatory and Senescent Proteins

With age, pro-inflammatory cytokines (IL-6, TNF-alpha), glycated proteins, and factors secreted by senescent cells (the so-called SASP, Senescence-Associated Secretory Phenotype) accumulate. These molecules promote chronic low-grade inflammation (inflammaging), which accelerates aging and increases the risk of chronic diseases.

A human study published in GeroScience (2022, PMID: 35999337) by Kim, Kiprov and colleagues from the Conboy Lab (UC Berkeley) observed reductions in some pro-inflammatory proteins and a proteomic shift toward younger reference profiles. These are biomarker signals, not clinical outcomes.

Environmental compounds bound to plasma

Some persistent organic pollutants, combustion products and lipophilic compounds travel bound to plasma proteins or lipoproteins. TPE may reduce part of that circulating fraction, but it does not replace specific heavy-metal strategies or exposure reduction.

Altered Macromolecules

• Advanced glycation end-products (AGEs): formed when sugar binds to proteins, accelerating vascular and neurological aging.
• Autoantibodies: in autoimmune diseases, the immune system produces antibodies against its own tissues.

What Does the Science Say: Key Studies

Therapeutic plasma exchange is not a passing fad. It has decades of clinical use. The new question is longevity, where evidence has moved quickly but still does not carry the weight of a classic hospital indication.

Key safety point: using TPE for longevity is investigational and outside established ASFA indications. It should not be presented as an approved “anti-aging treatment,” but as a medical intervention that only makes sense with a defined goal, labs, informed consent and stopping rules.

Question	What we know today	What is still missing
Does it work for serious diseases?	Yes, for specific therapeutic apheresis indications such as TTP, Guillain-Barré, myasthenia gravis and antibody-mediated rejection.	Indication should follow clinical guidelines and specialist assessment.
Can it modulate aging signals?	Human studies show changes in proteomics, inflammation, immunity and some biological clocks; one healthy-donor trial found no epigenetic rejuvenation.	Larger independent trials with comparable protocols and functional follow-up are still needed.
Does it remove microplastics?	2025-2026 studies suggest removal or reduction of circulating particles in some protocols.	We still need independent replication, toxicity thresholds and patient-centered outcomes.
Is it for everyone?	No. It is a medical procedure involving venous access, anticoagulation and volume replacement.	Candidate profile, goal, biomarkers and stopping rules should be defined first.

UC Berkeley — plasma dilution improves tissue markers in mice (2020)

Mehdipour et al. (Aging, 2020) demonstrated in mice that simple plasma dilution with saline and albumin (without adding young blood) improved markers in brain, liver and muscle. The finding changed the paradigm: part of the effect may come from reducing age-associated plasma factors, not from adding young blood.

The proposed mechanism is the attenuation of circulating inhibitors that accumulate with age and modulate signaling pathways related to tissue repair (JAK-STAT, TGF-beta, MAPK, NF-κB).

Plasma dilution and biological-age signals in humans (2022)

Kim et al., GeroScience (2022) — PMID: 35999337

Small longitudinal human study. The treated cohort included 8 middle-aged or older adults, compared with younger and older reference profiles, with repeated samples before and after several rounds of TPE. The results were biomarker-based, not clinical event outcomes:

• Reduction of oxidative DNA damage (8-OHdG marker)
• Decrease in p16 (cellular senescence marker)
• Changes in lymphocyte/myeloid balance: increase in T cells, B cells, NK cells; decrease in pro-inflammatory macrophages (CD68)
• Proteomic shift: 72 proteins that differentiated younger and older profiles moved toward more youthful levels after TPE

The study observed that TPE was associated with a proteomic shift toward younger reference profiles, with changes in pro-regenerative, anti-cancer and apoptotic regulators. The proposed mechanism recalibrates JAK-STAT, MAPK, TGF-beta, NF-κB and Toll-like receptor (TLR) signaling pathways, with TLR4 as a nodal point.

Controlled clinical trial — a 2.61-year biological-age signal (2025)

Fuentealba et al., Aging Cell (2025) — DOI: 10.1111/acel.70103

This is a small exploratory randomized trial with a simulated-procedure arm focused on human biological age. It included 42 adults over 50 (mean age close to 65) in a single-blind trial with four arms:

1. Biweekly TPE
2. Biweekly TPE + intravenous immunoglobulin (IVIG)
3. Monthly TPE
4. Placebo or simulated procedure

The TPE + IVIG group reduced average biological age by 2.61 years according to multi-omic biomarkers; biweekly TPE without IVIG showed a smaller average reduction of 1.32 years. Effects were clearest after the first three sessions and strongest in people with poorer baseline health: higher glucose, bilirubin or liver enzymes.

The honest interpretation is two-sided: this is the strongest human evidence available for TPE and aging biology, but it does not yet prove lower mortality, fewer cardiovascular events or durable functional improvement. The study was also industry-supported, several authors disclosed conflicts, and independent replication is needed.

Healthy-donor trial — negative epigenetic-clock signal (2025)

Borsky et al., Scientific Reports (2025) — PMID: 40592961 evaluated 4 or 8 plasmapheresis sessions in healthy adults over 18 weeks using an automatic plasma collection system, without young plasma or albumin replacement. The protocol changed lipids, total proteins, albumin and some hematologic markers, but did not show significant epigenetic rejuvenation. Instead, DNAmGrimAge, the Hannum clock and Dunedin Pace of Aging increased.

This does not invalidate Fuentealba et al.; it studies a different population and protocol. But it blocks a simplistic message: plasmapheresis alone should not be sold as guaranteed rejuvenation. In longevity medicine, the indication should depend on biomarkers, inflammatory burden, replacement strategy, safety and measurable goals.

Apheresis and Microplastics (2025-2026)

The Brain Medicine study (2025, PMC: 12162106) is an early signal that double-filtration therapeutic apheresis may remove microplastic-like particles from extracted material. In 21 patients, 14 polymer-like signals were detected in eluate/removed material, including polyamide 6 (67.5% match) and polyurethane (35.3%). In 2026, Weinstein et al. (Journal of Clinical Apheresis, DOI: 10.1002/jca.70135) reported lower circulating microplastic counts after TPE in people with moderate-to-high starting levels. Both findings are relevant, but they do not yet prove direct clinical benefit, durable tissue-burden reduction or a universal preventive indication.

Other relevant studies, including cautionary data

• Kiprov, Transfusion and Apheresis Science (2021): editorial on TPE, blood products and longevity implications; useful context, but not a clinical trial.
• Healthy donor plasmapheresis trial (PMC12218284, 2025): repeated plasma collections without albumin or young plasma replacement lowered lipids, total proteins and albumin, but did not show epigenetic rejuvenation; some clocks such as DNAmGrimAge, Hannum and Dunedin Pace of Aging worsened. This is not the same protocol as therapeutic TPE, but it shows why protocol design matters.
• Double-filtration studies: show biomarker changes, but they are usually small, heterogeneous and do not prove durable clinical benefit.

What Is Therapeutic Plasma Exchange Used For?

TPE has two worlds of application: conventional medicine, with established indications, and longevity medicine, where it is being studied as a higher-intensity intervention for selected profiles.

In Conventional Medicine (Established Indications)

The 2023 ASFA guidelines review 91 clinical fact sheets and 166 graded therapeutic apheresis indications. ASFA does not say TPE “works” or “does not work” in the abstract: it categorizes indications. Category I means first-line or part of first-line care; II means second-line or supportive care; III requires individualized decision-making; IV means apheresis is considered ineffective or potentially harmful.

A technical review by Pham, Staley and Schwartz (2019, PMID: 31085053) summarizes TPE use across ASFA category I and II indications and classifies clinical timing into emergent, urgent and routine procedures. This matters because TPE is not generic “blood cleaning”: indication, urgency and replacement strategy change the benefit-risk calculation.

ASFA frame	Common examples	What it does not mean
Category I / established use	Thrombotic thrombocytopenic purpura, Guillain-Barré syndrome, severe myasthenia gravis, hyperviscosity in gammopathies.	It does not mean everyone with similar symptoms should receive TPE.
Category II / supportive or second-line	Some antibody-mediated, neurological, renal or post-transplant contexts.	It does not replace disease-specific treatment or specialist assessment.
Category III-IV / uncertain or not recommended	Uses where evidence is insufficient, conflicting or case-dependent.	It should not be presented as standard care, especially not as a generic wellness protocol.
Longevity	Not an established ASFA indication.	If considered, it should be individualized clinical investigation with consent, metrics and stopping rules.

In Longevity Medicine (The New Paradigm)

The longevity application should not be sold as a universal anti-aging treatment or as an established ASFA indication. It makes more sense as an investigational medical intervention to test whether reducing inflammatory burden and plasma factors improves measurable biomarkers in a specific person.

1. Reduce inflammaging (chronic low-grade inflammation): may reduce selected circulating biomarkers such as fibrinogen, some cytokines or plasma proteins, depending on protocol and baseline profile.
2. Explore environmental burden: the hypothesis around microplastics and other compounds is interesting, but still needs quantitative measurement, independent replication and clinical outcomes.
3. Modulate immune function: explore, when biomarkers justify it, changes in lymphocyte/myeloid balance and immunosenescence signals.
4. Optimize the cellular environment: the hypothesis is that reducing selected circulating inhibitors of pathways such as JAK-STAT, MAPK or TGF-beta may support a more favorable tissue environment; durable clinical outcomes are still unproven.
5. "Phase zero" before other treatments: TPE can be considered before interventions such as NAD+ IV or hyperbaric oxygen, but only with a goal and response metric.
6. Evaluate symptoms: some people report mental clarity or energy, but symptoms should be interpreted alongside biomarkers, not as proof on their own.

How to Decide: 7 Clinical Questions

The difference between a serious medical intervention and an expensive trend is the quality of the questions asked before treatment. Before considering TPE for longevity, answer:

1. Concrete goal: lower inflammation, prepare another therapy, improve symptoms or move a defined biomarker?
2. Baseline biomarkers: hsCRP, suPAR, IL-6, fibrinogen, ApoB, glucose, insulin, HbA1c, liver and kidney function, albumin, coagulation and complete blood count.
3. Vascular and venous risk: good venous access, anemia, anticoagulation, recent bleeding or hemodynamic instability?
4. Less invasive alternatives: strength training, Mediterranean diet, visceral fat loss, sleep and ApoB control often deliver higher returns if basics are missing.
5. Protocol type: TPE with albumin, TPE with IVIG, double filtration and plasma donation are not the same intervention.
6. Success metric: define what should improve and by when before repeating sessions.
7. Follow-up: repeat labs after 4-12 weeks and do not treat subjective sensations as proof.

What a Therapeutic Plasma Exchange Session Is Like

Before the session: preparation

• Pre-session blood test: complete blood count, kidney function, liver function, electrolytes, total proteins, albumin. This confirms you're a candidate and allows protocol adjustment.
• Medical evaluation: the medical team reviews your history, current medication, objectives (clinical vs. longevity).
• Informed consent: benefits, risks, and procedure are explained.

During the session

1. Placement of intravenous lines: typically two lines are used (one in each arm). If not possible, a double-lumen catheter is used.
2. Circuit initiation: blood flows continuously. Through one line it exits, passes through the machine, is centrifuged, plasma is separated, replaced with albumin, and returns through the other line.
3. Sensations: most patients feel nothing or only a slight feeling of cold (because the returned blood is at a slightly lower temperature than body temperature). You can read, watch a series, work on your laptop, or simply relax.
4. Duration: hospital apheresis units often describe sessions of about 2-3 hours; in specific protocols it varies with body weight, venous access, exchanged plasma volume and replacement strategy.
5. Completion: lines are removed, pressure is applied to the puncture points (as in a normal blood draw), and done.

After the session

• Practical recovery: hospital guidance commonly recommends good hydration, eating before the session when medically allowed and arranging support if tiredness or light-headedness occurs afterwards.
• Immediate effects (24-48h): some people report more energy or mental clarity, although this should not be the only success criterion.
• Medium-term effects (weeks): symptoms, recovery and stress tolerance should be compared with the baseline state.
• Long-term effects (months): reduction in inflammatory biomarkers (hsCRP, suPAR, fibrinogen) or changes in biological age if measured with epigenetic clocks.

Typical Protocol

• For longevity: cycles of 3-6 sessions spaced 1-4 weeks depending on objective and individual response.
• For autoimmune diseases: more intensive protocols (daily or 2-3 times per week) depending on pathology.

What to measure before and after

Timing	Useful markers	Why they matter
Before	Complete blood count, ferritin, albumin, total protein, electrolytes, kidney/liver function, coagulation	Safety, procedure tolerance and exchange-volume planning.
Before and 4-12 weeks after	hsCRP, suPAR, IL-6, fibrinogen, glucose, insulin, HbA1c, ApoB, blood pressure, HRV when available	Confirms whether inflammation and cardiometabolic risk actually move.
Optional	Biological/epigenetic age, proteomics, metabolomics or contaminant panels	Useful in research or advanced programs, but should not be the only success criterion.

Possible Side Effects

Most common (mild): bruising at the puncture site, dizziness or temporary fatigue (resolves in hours), feeling of cold during the procedure.

Rare: infection at the puncture site (low risk with proper sterile technique), allergic reaction to replacement fluid, citrate-related hypocalcemia (tingling, cramps or numbness), hypotension, arrhythmias, bleeding, transient reduction in immunoglobulins or clotting factors and complications from central venous access if used.

Absolute or high-risk contraindications: severe hemodynamic instability, known allergy to the replacement fluid, active uncontrolled bleeding, relevant anemia or coagulopathy, significant active infection or inability to obtain safe venous access.

TPE can be safe when performed by trained professionals with proper equipment, but it should not be trivialized as a wellness infusion.

Therapeutic plasma exchange cost: what changes the real price

Search results show very different price ranges because not every offer includes the same thing. A single plasmapheresis session, an albumin-based TPE cycle, double filtration and a medically supervised longevity protocol with labs and follow-up are not equivalent products.

Cost driver	Why it matters
Volume and number of sessions	A one-off session is different from a 3-6 session cycle with follow-up.
Replacement strategy	Albumin, donor plasma, IVIG and double filtration have different costs and goals.
Medical supervision	Safe TPE should include history, labs, coagulation/electrolyte checks and stopping rules.
Program context	The real value depends on whether it is linked to biomarkers, nutrition, exercise and follow-up.

Public market ranges: U.S., Spain/Europe and coverage

Scenario	Public range or reference	How to interpret it
U.S. private / wellness	Business Insider reported $5,000 to more than $10,000; Allen P. Green MD cites $6,000-$15,000+ per session; Extension Health publishes $10,000.	These are self-pay private-market prices. They are not medical evidence and not Progevita pricing.
Spain / private Europe	Clinica Planas Barcelona publishes 4,500 EUR per session; other private European references show variable ranges depending on country, technique, replacement fluid and care context.	Not all offers are equivalent: donor-style plasmapheresis, double filtration, albumin-based TPE and hospital packages can include different things.
Hospital / medical indication	Cost studies compare TPE with IVIG in specific diseases; insurer policies such as Aetna list medically necessary indications.	Recognized indications may require prior authorization and documentation. This is not comparable to a private longevity protocol.
3-6 session cycle	Total cost depends on sessions plus labs, albumin/plasma, IVIG if used, venous access, physician oversight and follow-up.	Compare the full budget and repeat/stop criteria, not only “price per session.”

As a practical guide, therapeutic plasma exchange usually requires a high-supervision medical budget, not a spa-treatment price. As market context, not medical evidence and not Progevita pricing, Business Insider reported US wellness-clinic offers from $5,000 to more than $10,000, while private US pages such as Allen P. Green MD cite $6,000-$15,000+ per session. Many private European offers sit roughly around 1,500-4,500 EUR per session, with major differences depending on replacement fluid, venous access, labs, medical oversight and follow-up. Hospital cost analyses are not comparable to wellness pricing: one myasthenia-gravis crisis study favored IVIG over PLEX on short-term acute cost, while a 2025 neurological cost analysis estimated lower direct costs for TPE than immunoglobulins in specific scenarios. Indication changes both the price and what that price means clinically.

What a TPE quote should include

Quote item	Why it matters
Baseline medical review and labs	Confirms whether anemia, coagulation, infection, electrolytes, albumin or kidney/liver markers make the procedure unsuitable or change the protocol.
Technique and replacement fluid	Albumin-based TPE, donor plasma, IVIG, double filtration and donor-style plasmapheresis do not have the same objective, risk profile or budget.
Venous access plan	Peripheral access and central venous access have different preparation, comfort and complication considerations.
Repeat/stop criteria	A responsible protocol defines the biomarker or clinical endpoint that justifies repeating, pausing or stopping treatment.
Follow-up window	Without 4-12 week follow-up, it is difficult to know whether inflammation, cardiometabolic risk or recovery markers actually changed.

The useful comparison is not “one session price” but three scenarios: an isolated assessment with one session, a 3-6-session cycle with interval labs, or a combined protocol involving IVIG, double filtration or other interventions. To compare the broader economics of a diagnostic longevity program, read our longevity clinic cost guide. Be cautious with offers promising “total detox,” guaranteed microplastic removal or rejuvenation without biomarkers.

Therapeutic Plasma Exchange at Progevita

At Progevita, therapeutic plasma exchange is not an isolated treatment. We integrate it within personalized longevity programs based on advanced diagnostics and 12-month follow-up.

Important clinical note: when considered for longevity, TPE is investigational and outside classic hospital indications. We do not present it as an approved anti-aging therapy or as a replacement for lifestyle, indicated medication or medical follow-up; it is only assessed when biomarkers, risks and measurable goals justify the discussion.

Our approach: measure burden, reduce it, sustain the response

1. Initial diagnosis: before any treatment, we measure more than 50 biomarkers: inflammation (hsCRP, suPAR, IL-6), metabolism (glucose, insulin, HbA1c), liver and kidney function, hormonal profile, body composition, VO2max, epigenetic age.
2. Plasma burden reduction phase: we aim to reduce inflammatory proteins, fibrinogen, immune complexes and, when measured, some compounds or particles associated with plasma.
3. Support and recovery phase: when the case supports it, we combine personalized IV support (for example NAD+ or high-dose vitamin C), ozone therapy for immune modulation, hyperbaric oxygen or bioidentical hormone therapy when indicated.
4. Follow-up and adjustment: at 3, 6, and 12 months we review biomarkers and adjust the protocol.

Specialized Medical Supervision

Plasma exchange at Progevita is performed by physicians specialized in longevity medicine with training in therapeutic apheresis. The protocol is decided after medical history, blood tests and risk review; it is not prescribed by calendar or as a generic “detox.”

Is Therapeutic Plasma Exchange Right for You?

Profiles worth a medical discussion: people aged 45-75 with repeated signs of chronic inflammation, relevant environmental exposure, autoantibodies or persistent symptoms such as fatigue and slow recovery. Markers like hsCRP > 1.5 mg/L or suPAR > 3 ng/mL can be conversation triggers, not automatic indications.

Not a priority if: low baseline inflammation and optimal metabolic health, age < 40 without risk factors, anemia, altered coagulation, active infection, major fear of venous access, or if exercise, nutrition, sleep, blood pressure, ApoB and body composition are still not addressed.

If you have doubts about whether plasma exchange can benefit you, consult with our medical team. We evaluate your case personally and propose the most appropriate plan.

👉 Start your longevity plan

Frequently Asked Questions

Is therapeutic plasma exchange the same as plasmapheresis?

In everyday clinical conversation they are often used interchangeably, but they are not technically identical. Plasmapheresis separates or removes plasma; therapeutic plasma exchange removes a clinically relevant volume and replaces it with albumin, compatible donor plasma or another indicated fluid. That replacement step is a major driver of both cost and risk.

Is plasma exchange painful?

No. It's similar to a blood draw with two intravenous lines. Some people feel a slight pressure when needles are placed, but the procedure itself is painless. Most patients read, work, or rest during the session.

How many sessions are needed to see results?

For longevity and optimization, some protocols use cycles of 3-6 sessions spaced 1-4 weeks apart, but this should be individualized. In Fuentealba et al. (2025), the clearest effects appeared after the first three sessions; that does not mean three sessions are necessary or appropriate for everyone. For autoimmune diseases, protocols are more intensive and depend on the clinical indication.

Does it remove microplastics from the blood?

Studies from 2025-2026 suggest that some apheresis or TPE protocols may remove or reduce circulating microplastic-like particles in selected profiles. Brain Medicine detected polymer-like signals in extracted material; Weinstein et al. reported lower counts in people with moderate-to-high starting levels. The field is still early: we need evidence for lower total body burden, symptom improvement, risk reduction and independent replication. It should not be sold as guaranteed microplastic removal.

Does plasma exchange have side effects?

Usually mild: bruising at the puncture site, dizziness or temporary fatigue, feeling cold and citrate-related calcium changes. Serious side effects are rare when TPE is performed with sterile technique, pre-screening and medical supervision, but they exist: hypotension, allergic reaction, bleeding, infection or venous-access complications.

How much does therapeutic plasma exchange cost?

The price varies depending on protocol, number of sessions, replacement fluid and whether it is combined with other treatments. In the private European market, many public references place one session around 1,500-4,500 EUR, but this is not an approved Progevita price and does not replace a medical quote. At Progevita, cost is assessed within a complete program with diagnostics, a clinical objective, follow-up and continuation criteria. To understand the cost structure of a longevity clinic, read this 2026 price guide and then consult with our team for a personalized assessment.

Is therapeutic plasma exchange covered by insurance?

It depends on the indication. When TPE is prescribed for a recognized medical condition, coverage may be possible through hospital pathways or insurer prior authorization. When it is offered for longevity, optimization or wellness, it is usually self-pay. The right question is not only “is it covered?” but “for which diagnosis, with which documentation and against which clinical alternative?”.

How long does the effect of plasma exchange last?

Changes may last weeks or months, but real duration depends on protocol, baseline biomarkers and lifestyle. Habits that reduce the effect: tobacco, excessive alcohol, sedentary lifestyle, pro-inflammatory diet and high pollution exposure. Habits that sustain it: Mediterranean diet, strength + cardio, quality sleep and stress management. Maintenance should not be calendar-based; it should be guided by biomarkers and tolerance.

What should I ask a clinic before booking TPE?

Ask which technique will be used (albumin-based TPE, donor plasma, IVIG, double filtration or donor-style plasmapheresis), how much plasma is exchanged, which labs are checked before and after, who signs the indication, how citrate/calcium is managed, what happens if venous access is poor or dizziness occurs and which data point will decide whether to repeat or stop. If the answer is only “it cleans your blood”, the medical plan is missing.

References

1. Connelly-Smith et al. (2023). "Guidelines on the Use of Therapeutic Apheresis in Clinical Practice — ASFA Ninth Special Issue." PMID: 37017433
2. Pham HP, Staley EM, Schwartz J. (2019). "Therapeutic plasma exchange — A brief review of indications, urgency, schedule, and technical aspects." PMID: 31085053
3. Bobati SS, Naik KR. "Therapeutic Plasma Exchange - An Emerging Treatment Modality in Patients with Neurologic and Non-Neurologic Diseases." J Clin Diagn Res, 2017. PMC: PMC5620780
4. Fuentealba et al. (2025). "Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange." Aging Cell. DOI: 10.1111/acel.70103
5. Borsky et al. (2025). "Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial)." Scientific Reports. PMID: 40592961
6. Kim et al. (2022). "Old plasma dilution reduces human biological age: a clinical study." GeroScience. PMID: 35999337
7. Mehdipour et al. (2020). "Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin." Aging. PMID: 32474458
8. "Therapeutic apheresis: A promising method to remove microplastics?" (2025). Brain Medicine. PMC: 12162106
9. Weinstein R et al. "Can Plasma Exchange Be Used to Lower the Circulating Burden of Microplastics in Human Patients?" Journal of Clinical Apheresis, 2026. DOI: 10.1002/jca.70135
10. Kiprov D. (2021). "Therapeutic plasma exchange (TPE) and blood products — Implications for longevity and disease." Transfusion and Apheresis Science. PMID: 34074614
11. Healthy donor plasmapheresis trial (2025). "Human clinical trial of plasmapheresis effects on biomarkers of aging." PMC: 12218284
12. Leslie et al. (2022). "Discovery and quantification of plastic particle pollution in human blood." Environment International. PMID: 35367073
13. Cleveland Clinic. "Plasmapheresis (Plasma Exchange): Therapy, Procedure & What It Is." Cleveland Clinic
14. American College of Rheumatology (2025). "Plasma Exchange (Plasmapheresis)." ACR patient guidance
15. UT Southwestern Medical Center. "Therapeutic Plasma Exchange: What to Expect." UT Southwestern
16. Johns Hopkins Pathology. "Therapeutic Plasma Exchange" patient education guide. Johns Hopkins PDF
17. Mandawat A et al. "Plasma Exchange vs. Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison Study." J Clin Neuromuscul Dis, 2011. PMC: PMC3291869
18. Antelo ML et al. "Cost analysis of treatment with therapeutic plasma exchange versus intravenous immunoglobulins in immune-based neurological diseases." Neurologia (Engl Ed), 2025. PMID: 40204254
19. Business Insider. "The hot new longevity treatment for aging athletes and CEOs is a plasma exchange", 2024. Business Insider. Used as market context only.
20. Allen P. Green MD. "How Much Does Therapeutic Plasma Exchange Cost?" Allen P. Green MD. Used as market context only.
21. Extension Health. "Therapeutic Plasma Exchange NYC." Extension Health. Used as market context only.
22. Clínica Planas. "Plasmapheresis treatment in Barcelona." Clínica Planas Barcelona. Used as market context only.
23. Aetna Clinical Policy Bulletin. "Plasmapheresis/Plasma Exchange/Therapeutic Apheresis." Coverage policy.

This article is for informational purposes and does not replace individual medical consultation. For longevity, therapeutic plasma exchange should be considered investigational/off-label and dependent on individual medical assessment.

Want to know if plasma exchange is right for you? Talk to our medical team and design a personalized protocol at Balneario de Cofrentes, Valencia.